Furthermore, four gene signatures for predicting immunotherapy response, including a six-gene IFNγ signature (34), a related 18-gene IFNγ signature (34), an effector T cell signature (35), a combined IFNγ/effector T cell signature (36), were significantly up-regulated in melanoma patients belonging to low promoter methylation group with high MYO1G gene expression level, supporting that MYO1G expression can predict prognosis in melanoma patients treated with immune checkpoint blockade. The gene discussed is IFNG; the disease is melanoma.